Merging Mylan Meanders Through 2008

Mylan's (NYSE: MYL  ) stock suffered ever since it announced it would acquire Merck KGaA's generic-drug business last May. In the larger-is-better world of generic-drug makers, it's kind of surprising that investors haven't gotten behind this deal. Fools who can look a little farther into the future might be set for a steal, after the stock dropped another 8% on Friday.

Year-over-year comparisons are rather useless, since Mylan doubled in size after the acquisition. Compared to last quarter, though, Mylan's revenue slipped about 9%. The company blamed much of that decrease on middlemen cutting its inventories. The one bright spot was its generic fentanyl patch, which gained a 50% market share after competitors Johnson & Johnson (NYSE: JNJ  ) and Novartis (NYSE: NVS  ) were forced to recall their products.

The synergies from Mylan's latest acquisition are beginning to work, however. Even with the lower revenue, adjusted income rose 11% quarter over quarter, thanks to higher adjusted gross margins and lower selling, general, and administrative costs. The company expects about $275 million in synergies by the end of 2008.

Mylan's biggest problem right now is that it's in debt up to its eyebrows -- $5.3 billion, to be exact. Fortunately, it does have a plan to pay down some of the debt. Mylan got $370 million when it sold off some of its royalty rights for high-blood-pressure medication Bystolic to Forest Labs (NYSE: FRX  ) , and it's also planning to sell its branded-drug business, Dey. Both should help Mylan get out of the giant hole it's dug itself into.

Mylan predicts that earnings per share will grow by a more-than-50% compounded annual rate for the next two years. Trading around 25 times 2008 expected earnings, Mylan looks like a steal at these prices, provided the company can make its synergies work.

Related Foolishness:


Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 643033, ~/Articles/ArticleHandler.aspx, 7/29/2014 3:51:26 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement